Royalty Pharma plc
Close on Nov 20, 2026Market cap $39.36BP/E 38.9Yield –
Royalty Pharma Total Leverage Ratio by Quarter
Total Leverage Ratio (Total Debt / Credit-Agreement Adjusted EBITDA) (×)
Royalty Pharma Total Leverage Ratio: 2.70× in Q3 2026.
Where the Q3 2026 figure comes from
“$8.8bn with weighted average duration of ~12 years; total leverage of 2.7x(1), net leverage of 2.5x(2)”
Source: Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗
Company-reported total debt divided by LTM Credit-Agreement Adjusted EBITDA.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Leverage Ratio (Total Debt / Credit-Agreement Adjusted EBITDA) (×) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2.70 | – | Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗ |
| Q2 2026 | Jun 30, 2026 | 2.80 | – | Royalty Pharma Quarterly Earnings Presentation (Q2 2026) ↗ |
| Q1 2026 | Mar 31, 2026 | 2.90 | – | Royalty Pharma Quarterly Earnings Presentation (Q1 2026) ↗ |
| Q4 2025 | Dec 31, 2025 | 3.00 | – | Royalty Pharma Quarterly Earnings Presentation (Q4 2025) ↗ |
Breakdown
What makes up total Leverage Ratio
Cite this data
StockData. (2026). Royalty Pharma Total Leverage Ratio (×), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Royalty Pharma SEC filings and investor materials. https://stockdatahq.com/stocks/rprx/kpis/total-leverage-ratio
See every metric in the Royalty Pharma KPI table. Data updated Nov 14, 2026.
See a number that looks wrong?